NASDAQ: HOWLWerewolf Therapeutics Inc Stock
$2.40+0.18 (+8.11%)
Updated Sep 19, 2024
HOWL Price
$2.40
Fair Value Price
$4.93
Market Cap
$104.89M
52 Week Low
$1.57
52 Week High
$8.19
P/E
-1.78x
P/B
1.01x
P/S
11.44x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.28M
Earnings
-$53.73M
Gross Margin
100%
Operating Margin
-521.88%
Profit Margin
-578.8%
Debt to Equity
0.48
Operating Cash Flow
-$41M
Beta
1.18
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
HOWL Overview
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics that stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Werewolf Therapeutics was incorporated in 2017 and is headquartered in Cambridge, MA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how HOWL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HOWL ($2.40) is undervalued by 51.31% relative to our estimate of its Fair Value price of $4.93 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
HOWL ($2.40) is significantly undervalued by 51.31% relative to our estimate of its Fair Value price of $4.93 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
HOWL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HOWL due diligence checks available for Premium users.
Be the first to know about important HOWL news, forecast changes, insider trades & much more!
HOWL News
Valuation
HOWL fair value
Fair Value of HOWL stock based on Discounted Cash Flow (DCF)
Price
$2.40
Fair Value
$4.93
Undervalued by
51.31%
HOWL ($2.40) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HOWL ($2.40) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HOWL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
HOWL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.78x
Industry
-135.85x
Market
25.52x
HOWL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.01x
Industry
6.51x
HOWL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HOWL's financial health
Profit margin
Revenue
$1.1M
Net Income
-$17.2M
Profit Margin
-1,509.1%
HOWL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
HOWL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$153.7M
Liabilities
$49.7M
Debt to equity
0.48
HOWL's short-term assets ($138.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HOWL's short-term assets ($138.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HOWL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.2M
Investing
-$17.0k
Financing
-$9.7M
HOWL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HOWL vs Biotech Stocks
Werewolf Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.